Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab and Bevacizumab with Radiotherapy in Advanced HCC
NCT05908916Phase 2Not yet recruiting
- Sponsor
- Yonsei University
- Start
- Jul 2023
- Primary completion
- Jul 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of atezolizumab, bevacizumab in hepatocellular carcinoma (HCC), sponsored by Yonsei University. Planned start Jul 2023; status: not yet recruiting.
02
Drugs
atezolizumabbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05908916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05908916.